Back to search
FDAFDA · Food and drugs·Recall number Z-0631-2022

ATTUNE REVISION POSTERIOR FEMORAL AUGMENT SZ 9 12MM-intended as a Component in total knee arthroplasty (TKA) revision surgeries Product Number: 154909003

Published February 16, 2022 · Recall initiated: January 5, 2022

Summary

FDA records medical device Class II recall Z-0631-2022, published February 16, 2022 and initiated January 5, 2022. Recalling firm: DePuy Orthopaedics, Inc.; Status: Terminated; Reported quantity: 6 units; Lot: Lots: JH9651, JH9649 GTIN: 10603295383178. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

May have adhesive residue on the posterior surface of the femoral augment, if undetected prior to implantation, soft tissue irritation and/or infection may occur.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
DePuy Orthopaedics, Inc.
Distributor
US Nationwide distribution in the states of TN, TX.
Lot
Lots: JH9651, JH9649 GTIN: 10603295383178
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was ATTUNE REVISION POSTERIOR FEMORAL AUGMENT SZ 9 12MM-intended as a Component in total knee arthroplasty (TKA) revision surgeries Product Number: 154909003 recalled?

Yes. FDA published recall Z-0631-2022 on February 16, 2022. Reported hazard: May have adhesive residue on the posterior surface of the femoral augment, if undetected prior to implantation, soft tissue irritation and/or infection may occur.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit